Articles from BioPorto A/S

BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals

News Release

By BioPorto A/S · Via GlobeNewswire · January 23, 2025

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

8 November 2024

By BioPorto A/S · Via GlobeNewswire · November 8, 2024

First Patient In - BioPorto Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL)™ for Adult Use at Massachusetts General Hospital

October 29, 2024Announcement no. 20

By BioPorto A/S · Via GlobeNewswire · October 29, 2024

BioPorto Enters Global Distribution Partnership with Beckman Coulter for Acute Kidney Injury NGAL Tests

28 October 2024Announcement no. 19

By BioPorto A/S · Via GlobeNewswire · October 28, 2024

BioPorto Presenting FDA-cleared ProNephro AKI (NGAL) at ASN Kidney Week 2024 Conference

By BioPorto A/S · Via GlobeNewswire · October 23, 2024

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

By BioPorto A/S · Via GlobeNewswire · October 22, 2024

BioPorto Announces Appointment of National Principal Investigator and Selection of CRO for Upcoming USA ICU Adult AKI Clinical Study

By BioPorto A/S · Via GlobeNewswire · October 10, 2024

BioPorto Announces NIH-Funded Study to Explore the Ability of Renal Biomarkers in Predicting Severe AKI, Advancing Beyond NLP-based AI Algorithms

July 30, 2024

By BioPorto A/S · Via GlobeNewswire · July 30, 2024

BioPorto to Debut FDA Approved ProNephro AKI at Upcoming ADLM 2024 Clinical Lab Expo

July 29, 2024

By BioPorto A/S · Via GlobeNewswire · July 29, 2024